RXSight Investors: Urgent Reminder on Class Action Lawsuit & Lead Plaintiff Deadline Approaching

NEW YORK – Faruqi & Faruqi, LLP, a leading national securities law firm, is issuing an urgent reminder to all investors who purchased RXSight, Inc. (NASDAQ: RXST) securities between October 27, 2022, and August 24, 2024, inclusive (the "Class Period"). Time is quickly diminishing for affected shareholders to seek the role of lead plaintiff in the pending class action lawsuit against RXSight.

The critical deadline for investors to file their motion to be appointed lead plaintiff is October 28, 2024.

The lawsuit alleges that RXSight, a company lauded for its innovative Light Adjustable Lens (LAL) and LAL Delivery System, made materially false and/or misleading statements and/or failed to disclose crucial information to investors during the specified Class Period.

Specifically, it is claimed that the company concealed significant manufacturing and supply chain challenges that were plaguing its operations. These undisclosed issues severely impacted the production and availability of RXSight's flagship LAL products, leading to substantial production shortages and, consequently, a detrimental reduction in sales and revenue.

Investors were allegedly kept in the dark about these critical operational impediments and their material impact on the company's financial health.

When the truth about these deep-seated manufacturing and supply chain problems eventually came to light, the market reacted sharply and negatively. RXSight's stock price experienced a significant decline, causing considerable financial harm to shareholders who had purchased their securities based on what is now alleged to be incomplete or misleading information.

The class action seeks to recover damages for investors under the federal securities laws.

If you purchased RXSight securities during the Class Period and suffered losses, you have the opportunity to move the Court to serve as lead plaintiff through counsel of your choice. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any potential recovery does not require that you serve as a lead plaintiff; however, becoming one allows you to play a vital role in overseeing the recovery process and helps ensure the best possible outcome for all affected investors.

We strongly encourage all affected investors to act before the October 28, 2024 deadline.

If you wish to discuss your rights, have any questions concerning this notice, or require more information regarding the lead plaintiff process, it is crucial to seek legal counsel promptly to understand your options and diligently protect your investment interests.